Statins are the cholesterol-lowering drugs. Do such drugs could be a part of cancer treatment as well? Such drugs works to lower cholesterol levels by blocking liver enzymes. It was thought that…
Category: Lung Cancer Drugs
Get an ideas about the lung cancer treatment drugs, here we provide only information about drugs not to advice them to take without proper doctor guideline. For information about lung cancer drugs browse.
Drug: Pemetrexed (Alimta) to Treat NSCLC
What is Pemetrexed? Pemetrexed is medically necessary for the treatment of non-small cell lung cancer. It is also known by its brand name Alimta. It belongs to the class of drugs known…
Drug: Vinblastin to Treat NSCLC
About Vinblastin Vinblastin is a cancer medication that interferes with the growth of cancer cells. It helps to slow down the spread of cancer in the body. This medication works by interfering…
Drug: Etoposide (VP-16) to Treat NSCLC
What is Etoposide? Etoposide is a medicine used to kill cancer cells. It works by stopping cancer cells to further divide and make new cells. It is one of the active drugs…
Drug: Irinotecan (Camptosar) to treat NSCLC
Chemotherapy has been shown to provide benefit in patients with non-small-cell lung cancer (NSCLC). Lung cancer remains the leading cause of cancer-related death among both men and women in the United States….
Drug: Vinorelbine (Navelbine) to treat NSCLC
Vinorelbine, a chemotherapy drug, is sold under the trade name of Navelbine to treat various types of cancer. It has been approved for treatment of non-small-cell lung cancer and works in damaging…
Drug: Gemcitabine (Gemzar) to Treat NSCLC
Gemcitabine, US brand name Gemzar, is an anti-cancer chemotherapy drug and belongs to the class of drugs known as antimetabolite. Antimetabolites are cell-cycle specific and they attack at specific phases in the…
Drug: Docetaxel (Taxotere) to Treat NSCLC
Docataxel or Taxotere is a medication that works to interfere with cell division. Approved by FDA, it is used in treatment of non-small-cell lung cancer. It has shown promising single-agent activity in…